Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 1 | $13,723 |
Sells | 133 | $89,472,443 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
27 Feb 2023 17:14 | ELVN | Enliven Therapeutics Inc | COMMODORE CAPITAL LP | 10% | 23 Feb 2023 | Purchase | 621.8 | 22.072 | 13,723 | I |
28 Aug 2023 16:20 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 24 Aug 2023 | Sale | 72,876 | 16 | 1,166,016 | I |
28 Aug 2023 16:20 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 24 Aug 2023 | Sale | 367,124 | 16 | 5,873,984 | I |
26 Sep 2023 19:37 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Sep 2023 | Sale | 12,000 | 13.8076 | 165,691 | D |
28 Sep 2023 16:27 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 26 Sep 2023 | Sale | 32,711 | 15 | 490,665 | I |
28 Sep 2023 16:27 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 26 Sep 2023 | Sale | 164,789 | 15 | 2,471,835 | I |
03 Oct 2023 19:40 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Sep 2023 | Sale | 12,000 | 13.6248 | 163,498 | D |
06 Nov 2023 16:42 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 03 Nov 2023 | Sale | 8,026 | 13.0824 | 104,999 | D |
06 Nov 2023 16:43 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 03 Nov 2023 | Sale | 8,546 | 13.0764 | 111,751 | D |
21 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 19 Dec 2023 | Sale | 200 | 13 | 2,600 | D |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 19 Dec 2023 | Sale | 255 | 13 | 3,315 | D |
21 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 20 Dec 2023 | Sale | 8,688 | 13.0117 | 113,046 | D |
21 Dec 2023 16:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 20 Dec 2023 | Sale | 7,779 | 13.0143 | 101,238 | D |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 20 Dec 2023 | Sale | 1,915 | 13.0232 | 24,939 | I |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 20 Dec 2023 | Sale | 2,110 | 13.0202 | 27,473 | D |
26 Dec 2023 19:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 21 Dec 2023 | Sale | 20 | 13 | 260 | D |
26 Dec 2023 19:32 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 21 Dec 2023 | Sale | 20 | 13 | 260 | D |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 21 Dec 2023 | Sale | 6 | 13 | 78 | I |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 21 Dec 2023 | Sale | 7 | 13 | 91 | D |
27 Dec 2023 17:26 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 22 Dec 2023 | Sale | 1,030 | 15.0728 | 15,525 | D |
27 Dec 2023 17:28 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 22 Dec 2023 | Sale | 983 | 15.0313 | 14,776 | D |
26 Dec 2023 19:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 22 Dec 2023 | Sale | 8,175 | 13.0465 | 106,655 | D |
26 Dec 2023 19:32 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 22 Dec 2023 | Sale | 6,546 | 13.066 | 85,530 | D |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 22 Dec 2023 | Sale | 168 | 13 | 2,184 | D |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 22 Dec 2023 | Sale | 35 | 13 | 455 | I |
28 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 26 Dec 2023 | Sale | 12,000 | 14.6424 | 175,709 | D |
27 Dec 2023 17:26 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 26 Dec 2023 | Sale | 100 | 15 | 1,500 | D |
27 Dec 2023 17:28 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 26 Dec 2023 | Sale | 102 | 15.005 | 1,531 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 28 Dec 2023 | Sale | 2,467 | 15.0742 | 37,188 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 28 Dec 2023 | Sale | 2,520 | 15.0776 | 37,996 | D |
03 Jan 2024 19:01 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Dec 2023 | Sale | 2,849 | 14.7818 | 42,113 | D |
03 Jan 2024 19:01 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Dec 2023 | Sale | 9,151 | 14.1261 | 129,268 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 29 Dec 2023 | Sale | 20 | 15 | 300 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 29 Dec 2023 | Sale | 20 | 15 | 300 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 02 Jan 2024 | Sale | 9,383 | 15.01 | 140,839 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 02 Jan 2024 | Sale | 11,000 | 15.0048 | 165,053 | D |
24 Jan 2024 18:38 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 22 Jan 2024 | Sale | 4,875 | 15.135 | 73,783 | D |
29 Jan 2024 20:01 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Jan 2024 | Sale | 9,458 | 15.8868 | 150,257 | D |
29 Jan 2024 20:01 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Jan 2024 | Sale | 2,542 | 14.9379 | 37,972 | D |
31 Jan 2024 21:20 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 29 Jan 2024 | Sale | 3,250 | 15.8118 | 51,388 | D |
31 Jan 2024 21:22 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Jan 2024 | Sale | 12,000 | 15.8547 | 190,256 | D |
01 Feb 2024 20:10 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 30 Jan 2024 | Sale | 1,270 | 16.4091 | 20,840 | D |
02 Feb 2024 16:29 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 31 Jan 2024 | Sale | 82,813 | 15 | 1,242,195 | I |
02 Feb 2024 16:29 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 31 Jan 2024 | Sale | 417,187 | 15 | 6,257,805 | I |
08 Feb 2024 20:47 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 Feb 2024 | Sale | 4,875 | 15.1094 | 73,658 | D |
16 Feb 2024 16:15 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 14 Feb 2024 | Sale | 136,642 | 14.9 | 2,035,966 | I |
16 Feb 2024 16:15 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 14 Feb 2024 | Sale | 688,358 | 14.9 | 10,256,534 | I |
20 Feb 2024 19:41 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Feb 2024 | Sale | 1,270 | 17.4153 | 22,117 | D |
28 Feb 2024 17:14 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 26 Feb 2024 | Sale | 4,376 | 17.2383 | 75,435 | D |
28 Feb 2024 17:14 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 26 Feb 2024 | Sale | 7,624 | 16.6866 | 127,219 | D |
29 Feb 2024 17:27 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Feb 2024 | Sale | 3,250 | 16.9732 | 55,163 | D |
04 Mar 2024 17:55 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Feb 2024 | Sale | 1,805 | 17.0938 | 30,854 | D |
04 Mar 2024 17:55 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Feb 2024 | Sale | 10,195 | 16.2974 | 166,152 | D |
08 Mar 2024 19:52 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 Mar 2024 | Sale | 4,875 | 15.6387 | 76,239 | D |
21 Mar 2024 18:41 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 19 Mar 2024 | Sale | 1,270 | 14.5029 | 18,419 | D |
22 Mar 2024 19:46 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 20 Mar 2024 | Sale | 13,278 | 19.1642 | 254,462 | D |
27 Mar 2024 17:03 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Mar 2024 | Sale | 7,329 | 17.1674 | 125,820 | D |
27 Mar 2024 17:03 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Mar 2024 | Sale | 4,671 | 18.1634 | 84,841 | D |
29 Mar 2024 17:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Mar 2024 | Sale | 182 | 18.7186 | 3,407 | D |
29 Mar 2024 17:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Mar 2024 | Sale | 3,068 | 18.2189 | 55,896 | D |
03 Apr 2024 21:30 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 01 Apr 2024 | Sale | 71 | 19.3578 | 1,374 | D |
03 Apr 2024 21:30 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 01 Apr 2024 | Sale | 9,577 | 18.8038 | 180,084 | D |
03 Apr 2024 21:30 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 01 Apr 2024 | Sale | 2,352 | 17.7242 | 41,687 | D |
03 Apr 2024 21:32 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 01 Apr 2024 | Sale | 3,237 | 19.0789 | 61,758 | D |
08 Apr 2024 20:40 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 04 Apr 2024 | Sale | 3,485 | 19.1476 | 66,729 | D |
10 Apr 2024 20:35 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 08 Apr 2024 | Sale | 544 | 19.3979 | 10,552 | D |
10 Apr 2024 20:35 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 08 Apr 2024 | Sale | 4,331 | 18.5025 | 80,134 | D |
12 Apr 2024 18:23 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 10 Apr 2024 | Sale | 13,600 | 21.0106 | 285,744 | D |
15 Apr 2024 19:04 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 11 Apr 2024 | Sale | 10,223 | 25.0386 | 255,970 | D |
15 Apr 2024 19:04 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 11 Apr 2024 | Sale | 3,777 | 23.8759 | 90,179 | D |
15 Apr 2024 19:05 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 11 Apr 2024 | Sale | 47,709 | 25.0414 | 1,194,700 | D |
15 Apr 2024 19:06 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 11 Apr 2024 | Sale | 30,000 | 25.0444 | 751,332 | D |
15 Apr 2024 19:06 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 11 Apr 2024 | Sale | 17,500 | 25.0342 | 438,098 | D |
15 Apr 2024 19:03 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 11 Apr 2024 | Sale | 649 | 25 | 16,225 | I |
15 Apr 2024 19:02 | ELVN | Enliven Therapeutics Inc | COLLINS HELEN LOUISE | CHIEF MEDICAL OFFICER | 11 Apr 2024 | Sale | 20,000 | 25.0739 | 501,478 | D |
15 Apr 2024 19:03 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 11 Apr 2024 | Sale | 5,045 | 25.0306 | 126,279 | D |
12 Apr 2024 18:23 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 11 Apr 2024 | Sale | 3,068 | 25.2094 | 77,342 | D |
12 Apr 2024 18:23 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 11 Apr 2024 | Sale | 20,032 | 24.9951 | 500,702 | D |
12 Apr 2024 18:23 | ELVN | Enliven Therapeutics Inc | BALLAL RAHUL D. | Director | 11 Apr 2024 | Sale | 30,300 | 23.1361 | 701,024 | D |
15 Apr 2024 19:03 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Apr 2024 | Sale | 80 | 20.6773 | 1,654 | D |
15 Apr 2024 19:03 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Apr 2024 | Sale | 1,190 | 19.9403 | 23,729 | D |
29 Apr 2024 18:50 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Apr 2024 | Sale | 12,000 | 16.8917 | 202,700 | D |
01 May 2024 19:02 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 29 Apr 2024 | Sale | 3,250 | 16.9737 | 55,165 | D |
01 May 2024 19:04 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Apr 2024 | Sale | 1,013 | 18.4823 | 18,723 | D |
01 May 2024 19:04 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Apr 2024 | Sale | 10,987 | 17.8634 | 196,265 | D |
07 May 2024 18:58 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 03 May 2024 | Sale | 1,000 | 22.5 | 22,500 | D |
08 May 2024 20:40 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 May 2024 | Sale | 4,875 | 22.7219 | 110,769 | D |
13 May 2024 19:35 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 09 May 2024 | Sale | 260 | 25.0596 | 6,515 | D |
16 May 2024 19:29 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 14 May 2024 | Sale | 1,107 | 25 | 27,675 | D |
20 May 2024 19:46 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 16 May 2024 | Sale | 1,270 | 23.7399 | 30,150 | D |
20 May 2024 17:00 | ELVN | Enliven Therapeutics Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 May 2024 | Sale | 1,000,000 | 22.14 | 22,140,000 | I |
20 May 2024 17:00 | ELVN | Enliven Therapeutics Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 May 2024 | Sale | 33,300 | 22.14 | 737,262 | I |
20 May 2024 17:03 | ELVN | Enliven Therapeutics Inc | GUPTA RISHI | Director , 10% | 16 May 2024 | Sale | 1,000,000 | 22.14 | 22,140,000 | I |
20 May 2024 17:03 | ELVN | Enliven Therapeutics Inc | GUPTA RISHI | Director , 10% | 16 May 2024 | Sale | 33,300 | 22.14 | 737,262 | I |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 100 | 24.34 | 2,434 | D |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 5,219 | 23.5715 | 123,020 | D |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 6,681 | 22.8643 | 152,756 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 10 | 24.34 | 243 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 2,334 | 23.4184 | 54,659 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 1,906 | 22.89 | 43,628 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)